Editas Medicine Inc
Suletud
SektorTervishoid
3.64 11.66
Ülevaade
Aktsiahinna muutus
24h
Min
3.61
Max
3.64
Sissetulek | -19M -25M |
|---|---|
Müük | -22M 2.8M |
Aktsiakasum | -0.26 |
Kasumimarginaal | -882.444 |
Töötajad | 87 |
EBITDA | -18M -23M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +97.26% upside |
Järgmine tulemuste avaldamine | 10. aug 2026 |
|---|
Turukapital | 173M 467M |
|---|---|
Eelmine avamishind | -8.02 |
Eelmine sulgemishind | 3.64 |
Editas Medicine Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Editas Medicine Inc Prognoos
Hinnasiht
By TipRanks
97.26% tõus
12 kuu keskmine prognoos
Keskmine 7.2 USD 97.26%
Kõrge 15 USD
Madal 4 USD
Põhineb 7 Wall Streeti analüütiku instrumendi Editas Medicine Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.